From Landmark CV Outcome Trials to the Front Lines of ASCVD Risk Reduction

Global Authorities on ACS, Interventional and Medical Cardiology, Lipid Medicine, ASCVD and Diabetes Answer FAQs: Focus on Trial-Based Evidence for PCSK9-Mediated LDL-C Lowering to Reduce CV Risk

Multi-Specialty

Featured Authorities on ASCVD Risk reduction

Dan Atar, MD

Dan Atar, MD

Head of Research
Oslo University Hospital Ulleval
Professor of Cardiology
University of Oslo
Oslo, Norway
Visiting Associate Professorship
Johns Hopkins University
Baltimore, Maryland

Christie M. Ballantyne, MD

Christie M. Ballantyne, MD

Director, Center for Cardiovascular Disease Prevention
Methodist DeBakey Heart Center
Chief of the Section of Cardiovascular Research
Director of Atherosclerosis Laboratory
Professor of Medicine
Baylor College of Medicine
Houston, TX

Deepak L. Bhatt

Deepak L. Bhatt, MD, MPH

Executive Director of Interventional Cardiovascular Programs
Brigham and Women’s Hospital Heart and Vascular Center
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Michael J. Blaha, MD, MPH

Michael J. Blaha, MD, MPH

Director of Clinical Research
Ciccarone Center for the Prevention of Heart Disease
Associate Professor of Medicine
Johns Hopkins School of Medicine
Baltimore, MD

Alberico Catapano, PhD

Alberico Catapano, PhD

Full Professor of Pharmacology
University of Milano
Director, Laboratory for the Study of Lipoproteins and Atherosclerosis
Immediate Past President, European Atherosclerosis Society (EAS)

Michael H. Davidson, MD, FACC, FACP, FNLA

Michael H. Davidson, MD, FACC, FACP, FNLA

Clinical Professor
Director of Preventive Cardiology
The University of Chicago Hospitals and Clinic
Pritzker School of Medicine
Chicago, Illinois

stefano del prato

Stefano Del Prato, MD PhD

Professor of Endocrinology and Metabolism
School of Medicine, University of Pisa
Chief of the Section of Diabetes
Clinical Associate Professor of Medicine
University of Texas, San Antonio Health Science Center
San Antonio, TX

Sergio Fazio, MD

Sergio Fazio, MD

Director, Center for Preventive Cardiology
Professor of Medicine
Division of Cardiovascular Medicine
School of Medicine
Oregon Health Sciences University (OHSU)
Portland, OR

Vivian Fonseca, MD

Vivian Fonseca, MD

Professor of Medicine and Pharmacology
Chief, Section of Endocrinology
Tulane University Health Sciences Center
New Orleans, LA
President, Science and Medicine (2012)
American Diabetes Association (ADA)

Keith A.A. Fox, MBChB, FRCP, FMedSci

Keith A.A. Fox, MBChB, FRCP, FMedSci

Professor, University of Edinburgh
Department of Cardiovascular Medicine
Professor, University and Royal Infirmary
Edinburgh, United Kingdom

Anne C. Goldberg, MD, FNLA, FACP, FAHA

Anne C. Goldberg, MD, FNLA, FACP, FAHA

Professor of Medicine
Division of Endocrinology, Metabolism & Lipid Research
Washington University
St. Louis, MO

Samuel Z. Goldhaber, MD

Samuel Z. Goldhaber, MD

Professor of Medicine
Harvard Medical School
Interim Chief, Division of Cardiovascular Medicine
Director, Thrombosis Research Group
Cardiovascular Division
Head, Vascular Medicine
Brigham and Women's Hospital
Boston, Massachusetts

Shaun Goodman, MD, MSc, FRCPC, FACC, FESC, FAHA

Shaun Goodman, MD, MSc, FRCPC, FACC, FESC, FAHA

Associate Head, Division of Cardiology
St. Michael’s Hospital
Professor, Department of Medicine
University of Toronto
Toronto, Ontario

J. Wouter Jukema, MD, PhD, FESC, FACC MC

J. Wouter Jukema, MD, PhD, FESC, FACC MC

Professor of Cardiology
Netherlands Heart Foundation
Chairman, Leiden Vascular Medicine
Leiden University Medical Center (LUMC)
Leiden, Netherlands

Ulf Landmesser MD, FESC

Ulf Landmesser MD, FESC

Professor of Cardiology
Medical Director, Department of Cardiology
Charite University Hospital
Berlin, Germany

Lawrence A. Leiter, MD

Lawrence A. Leiter, MD

Head, Division of Endocrinology and Metabolism
Director, Lipid Clinic
St. Michael’s Hospital
Professor, Medicine and Nutritional Sciences
University of Toronto
Toronto, Ontario, Canada

Stephen J. Nicholls, MD

Stephen J. Nicholls, MD

SAHMRI Deputy Director and Heart Foundation Heart Health Theme Leader
Professor of Cardiology
University of Adelaide
Consultant Cardiologist
Royal Adelaide Hospital
Adelaide, Australia

Paul Ridker, MD

Paul Ridker, MD

Eugene Braunwald Professor
Harvard Medical School
Division of Cardiovascular Medicine
Director, Center for Cardiovascular Disease Prevention
Brigham and Women’s Hospital
Boston, MA

Matthew T. Roe, MD

Matthew T. Roe, MD

Professor of Medicine
Duke Clinical Research Institute
Duke University School of Medicine
Durham, NC

Robert S. Rosenson, MD

Robert S. Rosenson, MD

Professor of Medicine (Cardiology)
Mount Sinai Icahn School of Medicine
Director, Cardiometabolics Unit
Mount Sinai Heart Institute
New York, NY

Christian Ruff, MD

Christian Ruff, MD

Principal Investigator, ENGAGE-AF Trial
TIMI Group
Director, General Cardiology
Brigham and Women’s Hospital
Assistant Professor of Medicine
Harvard Medical School
Boston, MA

Phillipe Gabriel Steg, MD

Phillipe Gabriel Steg, MD

Professor of Cardiology
Université Paris – Diderot, Sorbonne-Paris Cité
Professor, National Heart and Lung Institute
Imperial College, London, UK
Director, Coronary Care Unit
Hôpital Bichat
Paris, France

Eric Stroes, MD, PhD

Eric Stroes, MD, PhD

Professor
Department of Vascular Medicine
Academic Medical Center
Amsterdam, The Netherlands

Freek W A Verheugt, MD, PhD

Freek W A Verheugt, MD, PhD

Professor of Cardiology
Chairman of the Department of Cardiology
Heartcenter of the University Medical Center
Nijmegen, The Netherlands

Vincent Woo, MD, FRCPC

Vincent Woo, MD, FRCPC

University of Manitoba
Principal Investigator
Diabetes Research Group
John Buhler Research Centre
Winnipeg, Manitoba, Canada

R. Scott Wright, MD

R. Scott Wright, MD

Professor of Medicine
Department of Cardiovascular Medicine
Cardiovascular Division
Mayo Clinic

Professor Andreas Zeiher, MD

Prof. Andreas Zeiher, MD

Chairman of Medicine
Department of Cardiology, Angiology, and Nephrology
J. W. Goethe University
Frankfurt, Germany

ABOUT THIS PROGRAM
AND FACULTY DISCLOSURES
PCSK9-FOCUSED RESOURCES
and TRIALS

    iQ&A interactive Medical Intelligence Zone welcomes your questions and your participation in the iQ&A community.

Latest Videos |view all videos

Showing 1 - 12 of 162 results

Previous| 1 | 2 | 3 | 4 | 5 ...14 |Next

You have made the case for a call-to-action to treat LDL-C very aggressively in diabetic patients with known ASCVD. What is your rationale for this and how do the recent rials support your recommendation to treat diabetics with ASCVD aggressively? Video

You have made the case for a call-to-action to treat LDL-C very aggressively in diabetic patients with known ASCVD. What is your rationale for this and how do the recent rials support your recommendation to treat diabetics with ASCVD aggressively?

What is the profile of the diabetic patient in whom the diabetes specialist should strongly consider the LDL-C lowering and outcome-improving effects of PCSK9 inhibitors? How do we risk stratify populations for secondary prevention? Video

What is the profile of the diabetic patient in whom the diabetes specialist should strongly consider the LDL-C lowering and outcome-improving effects of PCSK9 inhibitors? How do we risk stratify populations for secondary prevention?

What is your analysis of the two major CV outcome trials and from a mortality end point perspective in what way do mortality outcome end points/results distinguish the ODYSSEY Outcomes Trial with alirocumab? Video

What is your analysis of the two major CV outcome trials and from a mortality end point perspective in what way do mortality outcome end points/results distinguish the ODYSSEY Outcomes Trial with alirocumab?

As a leading authority in LDL-C-mediated CV risk reduction, can you provide us with your perspective on the evidence for PCSK9 inhibitors as a foundational approach for managing a broad spectrum of patients with high risk coronary heart disease? Video

As a leading authority in LDL-C-mediated CV risk reduction, can you provide us with your perspective on the evidence for PCSK9 inhibitors as a foundational approach for managing a broad spectrum of patients with high risk coronary heart disease?

You have identified the challenges of accessing PCSK9 inhibitors for patients whose CV risk is genetic vs. those whose clinical course is characterized by progressive vascular events. How do you approach each subset with respect to LDL-C management? Video

You have identified the challenges of accessing PCSK9 inhibitors for patients whose CV risk is genetic vs. those whose clinical course is characterized by progressive vascular events. How do you approach each subset with respect to LDL-C management?

How large is the subgroup of diabetic patients who you feel are likely to appropriate candidates for PCSK9 inhibition to optimize CV risk reduction? And how does the lack of a safety signal influence your recommendations for this group? Video

How large is the subgroup of diabetic patients who you feel are likely to appropriate candidates for PCSK9 inhibition to optimize CV risk reduction? And how does the lack of a safety signal influence your recommendations for this group?

Based on ODYSSEY Outcomes, for which biological/metabolic risk markers do you feel that cardiologists and atherosclerosis specialists should strive to achieve LDL-C levels even more aggressive than those identified in the AHA Guidelines? Video

Based on ODYSSEY Outcomes, for which biological/metabolic risk markers do you feel that cardiologists and atherosclerosis specialists should strive to achieve LDL-C levels even more aggressive than those identified in the AHA Guidelines?

What is the unmet need for residual CV risk reduction in post-ACS patients with T2D? In your role as a member of the LDL Guideline Group for AACE, what were the implications of treating diabetic patients with so-called “extreme risk”?” Video

What is the unmet need for residual CV risk reduction in post-ACS patients with T2D? In your role as a member of the LDL Guideline Group for AACE, what were the implications of treating diabetic patients with so-called “extreme risk”?”

What are the principal concerns related to CV risk reduction in patients with T2D and where does LDL-C lowering with PCSK9 inhibitors fit into the clinical strategy? Video

What are the principal concerns related to CV risk reduction in patients with T2D and where does LDL-C lowering with PCSK9 inhibitors fit into the clinical strategy?

What did we learn specifically about the population of patients with post-ACS and T2D who were treated with alirocumab in the ODYSSEY Outcomes Trial? Video

What did we learn specifically about the population of patients with post-ACS and T2D who were treated with alirocumab in the ODYSSEY Outcomes Trial?

Which diabetic patients, in particular, should be prioritized for PCSK9-mediated CV risk reduction? Video

Which diabetic patients, in particular, should be prioritized for PCSK9-mediated CV risk reduction?

As the Director of the Center for Cardiovascular Disease Prevention, what patient types on the risk landscape of ASCVD do you believe deserve special attention because they are likely to be eligible candidates for PCSK9-mediated LDL-C reduction? Video

As the Director of the Center for Cardiovascular Disease Prevention, what patient types on the risk landscape of ASCVD do you believe deserve special attention because they are likely to be eligible candidates for PCSK9-mediated LDL-C reduction?

Showing 1 - 12 of 162 results

Previous| 1 | 2 | 3 | 4 | 5 ...14 |Next